Alison Moore
2021
In 2021, Alison Moore earned a total compensation of $3.5M as Chief Technical Officer at Allogene Therapeutics, a 43% increase compared to previous year.
Compensation breakdown
| Bonus | $75,000 |
|---|---|
| Non-Equity Incentive Plan | $180,500 |
| Option Awards | $1,963,489 |
| Salary | $475,000 |
| Stock Awards | $839,973 |
| Other | $13,050 |
| Total | $3,547,012 |
Moore received $2M in option awards, accounting for 55% of the total pay in 2021.
Moore also received $75K in bonus, $180.5K in non-equity incentive plan, $475K in salary, $840K in stock awards and $13.1K in other compensation.
Rankings
In 2021, Alison Moore's compensation ranked 3,762nd out of 12,415 executives tracked by ExecPay. In other words, Moore earned more than 69.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,762 out of 12,415 | 70th |
Division Manufacturing | 1,536 out of 5,508 | 72nd |
Major group Chemicals And Allied Products | 622 out of 2,378 | 74th |
Industry group Drugs | 551 out of 2,099 | 74th |
Industry Biological Products, Except Diagnostic Substances | 144 out of 449 | 68th |
Source: SEC filing on April 26, 2022.
Moore's colleagues
We found four more compensation records of executives who worked with Alison Moore at Allogene Therapeutics in 2021.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Allogene Therapeutics CEO David Chang receives $13M in 2018
April 24, 2019